Dendritic cells: On the move from bench to bedside
- 1 July 2001
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 7 (7) , 761-765
- https://doi.org/10.1038/89863
Abstract
As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.Keywords
This publication has 35 references indexed in Scilit:
- Will the Making of Plasmacytoid Dendritic Cells in Vitro Help Unravel Their Mysteries?The Journal of Experimental Medicine, 2000
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopesJournal of Clinical Investigation, 2000
- Dendritic cell immunotherapy for cancer: Application to low‐grade lymphoma and multiple myelomaImmunology & Cell Biology, 1999
- Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cellsJournal of Clinical Investigation, 1999
- Dendritic Cell Vaccines for Cancer ImmunotherapyAnnual Review of Medicine, 1999
- Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.The Journal of Experimental Medicine, 1996
- Proliferating dendritic cell progenitors in human blood.The Journal of Experimental Medicine, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro.The Journal of Experimental Medicine, 1985